Global Breast Cancer Liquid Biopsy Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 278.07 Million |
 Market Size (Forecast Year) |
USD 1,465.33 Million |
 CAGR |
% |
| Major Markets Players |
|
>全球乳腺癌液体活检市场，按产品（消耗品和试剂盒）、循环生物标志物（细胞外囊泡 (EV)、游离 DNA (cfDNA)、ctRNA、循环肿瘤细胞 (CTC)、cfRNA 等）、最终用户（实验室、医院、医生实验室、参考实验室、公共卫生实验室、研究机构、小分子实验室和病理实验室）——行业趋势和预测到 2030 年。
乳腺癌液体活检市场分析及规模
液体活检是一种非侵入性医疗程序，涉及分析体液样本（通常是血液）中存在的各种生物标志物，以检测和监测各种疾病，包括癌症。它为传统的组织活检提供了一种替代方法，传统组织活检需要侵入性程序来获取组织样本。它被用于检测乳腺癌，因为它对患者来说更方便，并且是一种侵入性较小的方法。
在液体活检中，循环肿瘤 DNA (ctDNA)、循环肿瘤细胞 (CTC)、外泌体和其他生物标志物会被分析，以提供有关肿瘤存在、基因突变、治疗反应和疾病进展的宝贵信息。该过程包括从患者身上采集血液样本、分离所需成分，并进行分子分析以检查与疾病相关的遗传物质或蛋白质。
Data Bridge Market Research 分析，2022 年全球乳腺癌液体活检市场规模为 2.7807 亿美元，到 2030 年将飙升至 14.6533 亿美元，预计预测期内复合年增长率为 23.09%。
由于乳腺癌病例的不断增加，消耗品部分在全球乳腺癌液体活检市场的产品部分中占据主导地位。除了对市场价值、增长率、细分市场、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。
乳腺癌液体活检市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史性的一年 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按产品（耗材和试剂盒）、循环生物标志物（细胞外囊泡 (EV)、游离 DNA (cfDNA)、ctRNA、循环肿瘤细胞 (CTC)、cfRNA 等）、最终用户（实验室、医院、医生实验室、参考实验室、公共卫生实验室、研究机构、小分子实验室和病理学实验室） |
|
覆盖国家 |
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), Agilent Technologies Inc. (U.S.), Merck KGaA (U.S.), QIAGEN (Germany), Abcam plc. (U.K.), Cell Signaling Technology Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), The Menarini Group (Italy), Genomic Health (U.S.), Johnson & Johnson Private Limited. (U.S.), Medtronic (Ireland), Siemens Healthineers (Germany), Biocept, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Fluxion Biosciences, Inc. (U.S.), FOUNDATION MEDICINE, INC. (U.S.), Sysmex Inostics Inc. (U.S.), ExoDx (U.S.), and Illumina, Inc. (U.S.) among others |
|
Market Opportunities |
|
Market Definition
Breast cancer liquid biopsy refers to the use of liquid biopsy techniques specifically for the detection and monitoring of breast cancer. It involves the analysis of biomarkers present in bodily fluids, typically blood, to gain insights into the presence of breast cancer, monitor disease progression, assess treatment response, and identify specific genetic mutations or alterations associated with the disease.
Global Breast Cancer Liquid Biopsy Market Dynamics
Drivers
- Rising prevalence of breast cancers
The growing prevalence of breast cancer in the current world is directly influencing the demand for specific diagnostics that offer more precision. Breast cancer liquid biopsy is a non-invasive, specialized, and precise diagnostics test emerging as a promising technique. This, in turn, has carved the way for market growth.
- Adoption of non-invasive diagnostic techniques
Breast cancer liquid biopsy offers a non-invasive alternative to traditional tissue biopsies which are invasive and can be associated with various risks and complications. Liquid biopsy provides a less burdensome and more patient-friendly approach to detecting and monitoring breast cancer, which is expected to drive market growth.
- Growing investment in healthcare facilities
Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor expected to drive market growth. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further expected to drive market growth.
Opportunities
- Early detection and screening programs
There is an opportunity to implement widespread breast cancer liquid biopsy screening programs, particularly for high-risk populations. By detecting breast cancer at an early stage, these programs can significantly improve survival rates and patient outcomes. This is expected to create an opportunity for market growth.
-
Integration with the standard of care
Breast cancer liquid biopsy has the potential to become an integral part of the standard of care for breast cancer diagnostics and monitoring. Integrating liquid biopsy into routine clinical practice can provide healthcare professionals with valuable information for making treatment decisions and assessing treatment responses, which is expected to create an opportunity for market growth.
Restraints/Challenges
- Lack of skilled professionals
Performing breast cancer liquid biopsy requires specialized skills and expertise, particularly in areas such as histopathology, molecular pathology, and interpretation of results. The shortage of skilled pathologists, technicians, and molecular biologists can hinder the widespread adoption and efficient implementation of breast cancer liquid biopsy, leading to delays in diagnosis and treatment. This is expected to restrain market growth.
-
Stringent regulatory requirements
The global breast cancer liquid biopsy market is subject to strict regulatory oversight, ensuring patient safety, accuracy, and quality of diagnostic tests. Obtaining regulatory approvals and complying with regulations can be time-consuming and costly, particularly for new diagnostic technologies and companion diagnostics. Stringent regulatory requirements may slow down the pace of innovation and market entry for new products, which is expected to restrain market growth.
The global breast cancer liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the global breast cancer liquid biopsy market, contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In March 2023, REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer. REVEAL GENOMICS machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors
- In March 2021, Roche launched DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research
Global Breast Cancer Liquid Biopsy Market Scope
The global breast cancer liquid biopsy market is segmented into three notable segments based on product, circulating biomarkers, and end users. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Consumables
- Kits
Circulating Biomarkers
- Extracellular Vesicles (EVs)
- Cell-free DNA (cfDNA)
- ctRNA
- Circulating Tumor Cells (CTCs)
- cfRNA
- Others
End Users
- Laboratories
- Hospitals
- Physician Laboratories
- Reference Laboratories
- Public Health Laboratories
- Research Institutes
- Small Molecular Laboratories
- Pathology Laboratories
Global Breast Cancer Liquid Biopsy Market Regional Analysis/Insights
The global breast cancer liquid biopsy market is analyzed and market size insights and trends are provided by country, product, circulating biomarkers, and end users as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
North America is expected to dominate the global breast cancer liquid biopsy market due to the rising prevalence of breast cancer in the region. In addition, the growing investment in healthcare infrastructure is expected to drive market growth.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the adoption of non-invasive diagnostic techniques, increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战，以及国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
全球乳腺癌液体活检市场还为您提供详细的市场分析，包括每个国家/地区资本设备医疗保健支出的增长、市场上不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管情景的变化及其对市场的影响。数据适用于 2010-2020 年的历史时期。
竞争格局和全球乳腺癌液体活检市场份额分析
全球乳腺癌液体活检市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
全球乳腺癌液体活检市场的一些主要市场参与者包括：
- F. Hoffmann-La Roche Ltd（瑞士）
- 赛默飞世尔科技公司（美国）
- 雅培（美国）
- 安捷伦科技公司（美国）
- 默克集团（美国）
- QIAGEN（德国）
- Abcam plc.（英国）
- Cell Signaling Technology Inc.（美国）
- Koninklijke Philips NV（荷兰）
- 美纳里尼集团（意大利）
- 基因组健康（美国）
- 强生私人有限公司。（美国）
- 美敦力（爱尔兰）
- 西门子医疗（德国）
- Biocept, Inc.（美国）
- Bio-Rad Laboratories, Inc.（美国）
- Fluxion Biosciences, Inc.（美国）
- 基金会医学有限公司（美国）
- Sysmex Inostics Inc.（美国）
- ExoDx（美国）
- Illumina 公司（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
